Display Options:
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Vascular endothelial growth factor receptor inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER; UROLOGY AND KIDNEY
THERAPEUTIC INDICATION: Blast Crisis; Breast Neoplasms; Carcinoma; Endometriosis; Gliosarcoma; Mesothelioma; Neoplasm Metastasis; Stomach Neoplasms; Adrenal Cortex Neoplasms; Biliary Tract Neoplasms; Carcinoid Tumor; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Leukemia, Myeloid, Acute; Melanoma; Myelodysplastic Syndromes; Nasopharyngeal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Salivary Gland Neoplasms; Sarcoma; Sarcoma, Alveolar Soft Part; Skin Neoplasms; Solitary Fibrous Tumors; Thyroid Neoplasms; Carcinoma, Pancreatic Ductal; Kidney Neoplasms; Carcinoma, Renal Cell; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Kelch-like ECH-associated protein 1 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: IMMUNE SYSTEM; MUSCULOSKELETAL; OTHER
THERAPEUTIC INDICATION: Gliosarcoma; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Psoriatic; Arthritis, Rheumatoid; Cerebral Hemorrhage; Ischemic Stroke; Lymphoma, T-Cell, Cutaneous; Severe Acute Respiratory Syndrome; Sleep Apnea, Obstructive; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Psoriasis; Immune System Diseases; Multiple Sclerosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Cytochrome P450 51 inhibitor
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY
THERAPEUTIC INDICATION: Tinea; Tinea Pedis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Norepinephrine transporter inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Depressive Disorder, Major
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Sarcoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Asthma; Hyperhidrosis; Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Brain Neoplasms; Endometriosis; Glioblastoma; Liver Diseases; Neoplasm Metastasis; Pancreatic Neoplasms; Renal Insufficiency; Chordoma; Colorectal Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Glioma; Lung Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Urogenital Neoplasms; Uterine Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alzheimer Disease
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Liver Diseases; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Feeding and Eating Disorders; Anxiety Disorders; Depressive Disorder, Major; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Tyrosine-protein kinase BTK inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: HEMATOLOGY
THERAPEUTIC INDICATION: Breast Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Glioblastoma; Hematologic Neoplasms; Leukemia, Lymphoid; Liver Diseases; Lung Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Amyloidosis; Anaphylaxis; Anemia, Hemolytic, Autoimmune; Burkitt Lymphoma; Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Neoplasms; Food Hypersensitivity; Hodgkin Disease; Leukemia; Leukemia, Hairy Cell; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Lymphoma, B-Cell, Marginal Zone; Melanoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Severe Acute Respiratory Syndrome; Graft vs Host Disease; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Neoplasms; Waldenstrom Macroglobulinemia
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: INTRAVENOUS
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Hepatitis B, Chronic; Lymphoma; Infections; Severe Acute Respiratory Syndrome; Hepatitis C; Hepatitis C, Chronic; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Renal Insufficiency, Chronic; Hepatitis C; Hepatitis C, Chronic; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Soluble guanylate cyclase positive allosteric modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CARDIOVASCULAR; OTHER; RESPIRATORY
THERAPEUTIC INDICATION: HIV Infections; Anemia, Sickle Cell; Coronary Disease; Cystic Fibrosis; Raynaud Disease; Scleroderma, Localized; Scleroderma, Systemic; Ulcer; Familial Primary Pulmonary Hypertension; Hypertension; Hypertension, Pulmonary
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder, Major; Depressive Disorder
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: CRL4(CRBN) E3 ubiquitin ligase inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Anemia, Sickle Cell; Burkitt Lymphoma; Castleman Disease; Hodgkin Disease; Immunoglobulin Light-chain Amyloidosis; Lymphoma, Non-Hodgkin; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Waldenstrom Macroglobulinemia; Amyloidosis, Familial; Graft vs Host Disease; Leukemia, Plasma Cell; Lung Diseases, Interstitial; Lymphoma, Large B-Cell, Diffuse; Medulloblastoma; Myeloproliferative Disorders; Plasmacytoma; Polycythemia Vera; Prostatic Neoplasms, Castration-Resistant; Pulmonary Fibrosis; Sarcoma; Sarcoma, Kaposi; Scleroderma, Systemic; Smoldering Multiple Myeloma; Telangiectasia, Hereditary Hemorrhagic; Primary Myelofibrosis; Immune System Diseases; Multiple Myeloma
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Brain Neoplasms; Glioma; Kidney Diseases; Liver Diseases; Multiple Myeloma; Adenocarcinoma, Follicular; Ameloblastoma; Carcinoma; Carcinoma, Non-Small-Cell Lung; Erdheim-Chester Disease; Lung Neoplasms; Melanoma; Thyroid Neoplasms; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cardiomyopathies; Alzheimer Disease; Cognitive Dysfunction
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Estrogen receptor modulator
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: PREGNANCY AND GYNECOLOGY
THERAPEUTIC INDICATION: Paget Disease, Extramammary; Atrophy; Dyspareunia; Menopause
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Breast Neoplasms; Gastroparesis; Hypospadias; Obesity, Morbid; Pain; Burns; Headache; Postoperative Nausea and Vomiting; Glaucoma
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Diabetes Mellitus, Type 2; Diabetes Mellitus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Malaria; Acquired Immunodeficiency Syndrome; Amyotrophic Lateral Sclerosis; HIV Infections; Infections; Virus Diseases
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Asthma; Pulmonary Disease, Chronic Obstructive
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Epidermal growth factor receptor erbB1 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; OTHER
THERAPEUTIC INDICATION: Multiple Myeloma; Carcinoma, Non-Small-Cell Lung
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Carcinoma, Non-Small-Cell Lung; Opioid-Related Disorders; Brain Injuries; Ileus; Constipation
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Diagnostic agent
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alzheimer Disease; Cognitive Dysfunction
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Sodium/glucose cotransporter 2 inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: DIABETES DRUGS & ENDOCRINOLOGY; OTHER
THERAPEUTIC INDICATION: Aging; Alzheimer Disease; Pancreatic Neoplasms; Prostatic Neoplasms; Reperfusion Injury; Albuminuria; Breast Neoplasms; Cystinuria; Diabetic Nephropathies; Diabetic Neuropathies; Heart Failure, Diastolic; Hypertension, Pulmonary; Hyperuricemia; Metabolic Syndrome; Myocardial Infarction; Obesity; Weight Loss; Atrial Fibrillation; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fatty Liver; Heart Failure; Non-alcoholic Fatty Liver Disease; Polycystic Ovary Syndrome; Renal Insufficiency; Renal Insufficiency, Chronic; Severe Acute Respiratory Syndrome; Diabetes Mellitus
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: PI3-kinase p110-delta subunit inhibitor
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: CANCER; HEMATOLOGY; OTHER
THERAPEUTIC INDICATION: Carcinoma, Pancreatic Ductal; Leukemia, Myeloid, Acute; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Rhinitis, Allergic, Seasonal; Amyloidosis; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Lymphoma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Androgen Receptor agonist
ROUTE OF ADMINISTRATION: INTRAMUSCULAR; ORAL
STATUS: Approved
THERAPEUTIC AREA: DIABETES DRUGS & ENDOCRINOLOGY
THERAPEUTIC INDICATION: Carcinoma, Renal Cell; Coronary Disease; Prostatic Neoplasms, Castration-Resistant; Sexual Dysfunction, Physiological; Spinal Cord Injuries; Aging; Malnutrition; Respiratory Insufficiency; Hypogonadism; Klinefelter Syndrome; Neoplasms; Orchitis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Phosphodiesterase 4 inhibitor
ROUTE OF ADMINISTRATION: ORAL; UNKNOWN
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY; IMMUNE SYSTEM; OTHER; RHEUMATOLOGY
THERAPEUTIC INDICATION: Lupus Erythematosus, Discoid; Uveitis; Acne Vulgaris; Alcoholism; Arthritis, Rheumatoid; Colitis, Ulcerative; Dermatitis; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dermatomyositis; Eczema; Gout; Hidradenitis Suppurativa; Lichen Planus; Lichen Planus, Oral; Prostatitis; Rosacea; Vitiligo; Behcet Syndrome; Influenza, Human; Pneumonia; Severe Acute Respiratory Syndrome; Spondylitis, Ankylosing; Arthritis, Psoriatic; Immune System Diseases; Oral Ulcer; Psoriasis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Leucine-tRNA ligase inhibitor
ROUTE OF ADMINISTRATION: TOPICAL
STATUS: Approved
THERAPEUTIC AREA: DERMATOLOGY
THERAPEUTIC INDICATION: Onychomycosis
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Melatonin receptor agonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: EYE
THERAPEUTIC INDICATION: Kidney Diseases; Liver Diseases; Depressive Disorder, Major; Sleep Disorders, Circadian Rhythm; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Smith-Magenis Syndrome
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Orexin receptor antagonist
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: NEUROLOGY DRUGS & NERVOUS SYSTEM; OTHER
THERAPEUTIC INDICATION: Sleep Apnea Syndromes; Tobacco Use Disorder; Alcoholism; Alzheimer Disease; Opioid-Related Disorders; Restless Legs Syndrome; Sleep Wake Disorders; Smoking Cessation; Delirium; Sleep Initiation and Maintenance Disorders
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: DNA gyrase inhibitor
ROUTE OF ADMINISTRATION: OTIC
STATUS: Approved
THERAPEUTIC AREA: ENT
THERAPEUTIC INDICATION: Otitis Media; Pyelonephritis; Urinary Tract Infections; Otitis Externa
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hematologic Neoplasms; Gaucher Disease